18 F-FDG PET/CT in a Patient With Bilateral Perinephric Myxoid Pseudotumor of Fat.

Clin Nucl MedApr 13, 2026 (epub)
Case ReportNephrologyRadiology (Diagnostic)

Xuhe Liao, Zhanli Fu

✦ AI-curated · Sources linked

Case in brief

A 62-year-old man with nephrotic syndrome due to focal segmental glomerulosclerosis presented with masses around both kidneys. Contrast-enhanced CT showed large lesions encasing the kidneys and extending into the renal sinuses, with mild progressive enhancement and no renal cortical invasion. PET/CT demonstrated mild-to-moderate 18 F-FDG avidity. Core needle biopsy established the diagnosis of perinephric myxoid pseudotumor of fat.

What made this case unusual

The bilateral lesions encased the kidneys and extended into the renal sinuses, yet showed no cortical invasion; PET/CT demonstrated mild-to-moderate 18 F-FDG avidity.

Diagnostic / clinical pearl

Perinephric masses with renal sinus extension and FDG avidity require tissue diagnosis; in this case, core needle biopsy identified perinephric myxoid pseudotumor of fat.

Source

PubMed · PMID 42007848

Published in Clin Nucl Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Nephrology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.